
Boston-based Haemonetics agreed to buy Attune for an upfront cash payment of $160 million just under a month ago.
Chicago-based Attune medical develops the ensoETM proactive esophageal cooling device. The company designed ensoETM to reduce the likelihood of ablation-related esophageal injury. These injuries occur as a result of radiofrequency (RF) cardiac ablation procedures. ensoETM received FDA authorization for RF ablation in September 2023.
Haemonetics said its acquisition also includes contingent consideration based on sales growth over the next three years. It also hinges on the achievement of other certain milestones, according to a news release.
According to Haemonetics, Attune Medical generated approximately $22 million in revenue during its last fiscal year. In fiscal 2025, Haemonetics projects approximately $30 million to $35 million in revenue to come out of Attune. The company expects approximately 5¢-10¢ in contribution to its earnings per diluted share on a GAAP basis. For adjusted EPS, which exclude one-time acquisition- and integration-related costs, Haemonetics expects 10¢-15¢ from Attune.
Haemonetics financed the acquisition through a combination of cash on hand and a $150 million draw under its revolving credit facility.
This acquisition marks Haemonetics’ second major buy in recent months. The company acquired cardiology-focused medical device company OpSens in December 2023.